MAPT and Alzheimer disease: Recently, plasma biomarker studies [36–40] and the latest NIA-AA research framework proposed by Jack and colleagues in AAIC suggest using a combination of plasma Aβ42/Aβ40 and plasma p-Tau, rather than each alone, to identify individuals at a high risk of AD.